Astria Therapeutics (ATXS) News Today → Buy this small stock before coming AI Tidal Wave (From Chaikin Analytics) (Ad) Free ATXS Stock Alerts $9.00 +0.15 (+1.69%) (As of 03:22 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 5, 2024 | marketbeat.comArmistice Capital LLC Purchases New Shares in Astria Therapeutics, Inc. (NASDAQ:ATXS)Armistice Capital LLC purchased a new stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 1,578,000 shares of tJune 4, 2024 | businesswire.comAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2, 2024 | americanbankingnews.comAstria Therapeutics (NASDAQ:ATXS) Trading Up 4.7%May 30, 2024 | businesswire.comAstria Therapeutics to Present at Upcoming Jefferies Healthcare ConferenceMay 24, 2024 | businesswire.comAstria Therapeutics to Present at Upcoming Eastern Allergy ConferenceMay 23, 2024 | businesswire.comAstria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology CongressMay 22, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Astria Therapeutics (ATXS)May 21, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) PT Lowered to $25.00Oppenheimer reduced their target price on shares of Astria Therapeutics from $29.00 to $25.00 and set an "outperform" rating on the stock in a report on Tuesday.May 11, 2024 | finance.yahoo.comWe're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn RateMay 10, 2024 | marketbeat.comAstria Therapeutics' (ATXS) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $16.00 price objective on shares of Astria Therapeutics in a report on Friday.May 9, 2024 | markets.businessinsider.comATXS Stock Earnings: Astria Therapeutics Misses EPS for Q1 2024May 9, 2024 | businesswire.comAstria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateMay 9, 2024 | marketbeat.comVivo Capital LLC Buys 801,528 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS)Vivo Capital LLC boosted its stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 47.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,482,727 shares of the biotechnology company'sMay 8, 2024 | businesswire.comAstria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual MeetingMay 2, 2024 | businesswire.comAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 27, 2024 | marketbeat.comAstria Therapeutics, Inc. (NASDAQ:ATXS) is Vivo Capital LLC's 10th Largest PositionVivo Capital LLC reduced its position in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 6.2% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,329,027 shares of the biotechnology company's stock after selling 153,70April 23, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Trading Down 2.9% on Analyst DowngradeAstria Therapeutics (NASDAQ:ATXS) Trading Down 2.9% After Analyst DowngradeApril 23, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Price Target Cut to $16.00 by Analysts at HC WainwrightHC Wainwright reduced their price objective on Astria Therapeutics from $18.00 to $16.00 and set a "buy" rating on the stock in a research report on Tuesday.April 17, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Stock Price Down 2.4%Astria Therapeutics (NASDAQ:ATXS) Shares Down 2.4%April 16, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Shares Up 2.9%Astria Therapeutics (NASDAQ:ATXS) Trading Up 2.9%April 9, 2024 | businesswire.comAstria Therapeutics Appoints Sunil Agarwal to Its Board of DirectorsApril 3, 2024 | finance.yahoo.comChief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc (ATXS)April 3, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Shares Down 3.4% Astria Therapeutics (NASDAQ:ATXS) Trading Down 3.4%March 31, 2024 | marketbeat.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest UpdateAstria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) saw a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 2,010,000 shares, an increase of 18.2% from the February 29th total of 1,700,000 shares. Based on an average daily volume of 1,040,000 shares, the days-to-cover ratio is presently 1.9 days. Currently, 4.5% of the company's shares are sold short.March 27, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Sees Unusually-High Trading VolumeAstria Therapeutics (NASDAQ:ATXS) Sees Strong Trading VolumeMarch 26, 2024 | markets.businessinsider.comBuy Recommendation for Astria Therapeutics Backed by Promising ALPHA-STAR Trial ResultsMarch 26, 2024 | marketbeat.comWedbush Reiterates "Outperform" Rating for Astria Therapeutics (NASDAQ:ATXS)Wedbush reissued an "outperform" rating and set a $17.00 target price on shares of Astria Therapeutics in a research report on Tuesday.March 26, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Price Target Increased to $27.00 by Analysts at Jefferies Financial GroupJefferies Financial Group upped their target price on shares of Astria Therapeutics from $22.00 to $27.00 and gave the stock a "buy" rating in a research note on Monday.March 25, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY) and Astria Therapeutics (ATXS)March 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for Astria Therapeutics on Promising STAR-0215 Data and Market PotentialMarch 25, 2024 | marketbeat.comAstria Therapeutics' (ATXS) Buy Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and issued a $18.00 target price on shares of Astria Therapeutics in a report on Monday.March 25, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Reaches New 12-Month High at $16.90Astria Therapeutics (NASDAQ:ATXS) Hits New 1-Year High at $16.90March 25, 2024 | markets.businessinsider.comAstria Therapeutics Reports Positive Initial Results From ALPHA-STAR Trial - Quick FactsMarch 25, 2024 | finance.yahoo.comAstria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAEMarch 23, 2024 | finance.yahoo.comAstria Therapeutics, Inc. (NASDAQ:ATXS) is favoured by institutional owners who hold 53% of the companyMarch 20, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Stock Price Down 6.9%Astria Therapeutics (NASDAQ:ATXS) Shares Down 6.9%March 19, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Trading Up 3.8%Astria Therapeutics (NASDAQ:ATXS) Shares Up 3.8%March 16, 2024 | marketbeat.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Sees Significant Decline in Short InterestAstria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) was the recipient of a large decline in short interest during the month of February. As of February 29th, there was short interest totalling 1,700,000 shares, a decline of 13.3% from the February 14th total of 1,960,000 shares. Approximately 3.8% of the company's stock are sold short. Based on an average daily trading volume, of 790,400 shares, the short-interest ratio is presently 2.2 days.March 15, 2024 | finance.yahoo.comATXS Apr 2024 2.500 putMarch 15, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Hits New 52-Week High at $15.87Astria Therapeutics (NASDAQ:ATXS) Sets New 52-Week High at $15.87March 6, 2024 | marketbeat.comWedbush Comments on Astria Therapeutics, Inc.'s FY2028 Earnings (NASDAQ:ATXS)Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) - Wedbush issued their FY2028 earnings estimates for shares of Astria Therapeutics in a report issued on Monday, March 4th. Wedbush analyst L. Chico expects that the biotechnology company will post earnings per share of ($1.06) for the year. WMarch 5, 2024 | businesswire.comAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 5, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL) and Astria Therapeutics (ATXS)March 5, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Arcellx Inc (ACLX), Astria Therapeutics (ATXS)March 5, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Shares Gap Down Following Weak EarningsAstria Therapeutics (NASDAQ:ATXS) Shares Gap Down After Earnings MissMarch 5, 2024 | marketbeat.comAstria Therapeutics' (ATXS) Outperform Rating Reaffirmed at WedbushWedbush reissued an "outperform" rating and set a $17.00 price target on shares of Astria Therapeutics in a report on Tuesday.March 5, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Posts Quarterly Earnings Results, Misses Expectations By $0.08 EPSAstria Therapeutics (NASDAQ:ATXS - Get Free Report) released its quarterly earnings results on Monday. The biotechnology company reported ($0.86) earnings per share for the quarter, missing analysts' consensus estimates of ($0.78) by ($0.08).March 5, 2024 | marketbeat.comFmr LLC Sells 397,241 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS)Fmr LLC lessened its holdings in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 13.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,565,052 shares of the biotechnology company'sMarch 4, 2024 | businesswire.comAstria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate UpdateFebruary 27, 2024 | finance.yahoo.comATXS Oct 2024 22.500 call Get Astria Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXS and its competitors with MarketBeat's FREE daily newsletter. Email Address The #1 Crypto That You Don’t Own… Yet (Ad)There’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay attention to above all others: Venture capital firms. You want to follow venture capital money into cryptocurrencies before anyone gets word of what’s happening. Click here for all the details… ATXS Media Mentions By Week ATXS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATXS News Sentiment▼0.930.76▲Average Medical News Sentiment ATXS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATXS Articles This Week▼22▲ATXS Articles Average Week Get Astria Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Solid Biosciences News Today ImmuCell News Today Freeline Therapeutics News Today Zai Lab News Today Catalyst Pharmaceuticals News Today Galapagos News Today Keros Therapeutics News Today Evotec News Today Protagonist Therapeutics News Today NewAmsterdam Pharma News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATXS) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of ne...Chaikin Analytics | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | Sponsored[PDF Inside] Crypto's $1 Trillion 60-Day Boom + New 2024 Profit StrategyThe crypto industry is exploding and Chris Munch just released a new PDF detailing how you can potentially pro...DeFi Distribution | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | Sponsored